BTK and autoimmune thrombocytopenic purpura: Advances in deciphering the pathogenesis of ITP have facilitated the development of a number of new targeted therapies, such as those based on the inhibition of Syk inhibitors, Bruton’s tyrosine kinase (BTK), neonatal Fc receptors, or the complement pathway.